본문 바로가기

Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1KCI Q1
저널
Cancer Research and Treatment58(2) · pp.591 · 2026
피인용
Web of Science 1Scopus 1KCI 0
FWCI (Scopus)
1.83
JCR IF
JCR 2024 3.8
ISSN
1598-2998

저자

  1. 이혜원제1저자Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  2. 정의현Natl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
  3. 김경환Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
  4. 하홍구Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
  5. 오종진Seoul Natl Univ, Bundang Hosp, Dept Urol, Coll Med, Seongnam, South Korea
  6. 강석호Korea Univ, Coll Med, Dept Urol, Anam Hosp, Seoul, South Korea
  7. 정승환Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  8. 육현동Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  9. 허지은Yonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
  10. 함원식Yonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
  11. 황의창Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  12. 정승일Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  13. 송완Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  14. 임범진Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
  15. 홍범식Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
  16. 정병창Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  17. 서호경교신저자Natl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea

초록

PurposeThis study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).Materials and MethodsThis retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.ResultsPatients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.ConclusionOur research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.

키워드

TherapeuticsNon-muscle invasive bladder neoplasmsBacillus Calmette–GuérinFailureOrganization and administrationIntravesical administrationGemcitabineOrgan preservation

식별자

Scopus EID
2-s2.0-105035841246
WoS UID
001743756600021
KCI
ART003325921